Currently, predictive biomarkers for treatment response are lacking, but assessment of NF1 mutation status, pathway activation profiles, and liquid biopsy approaches like circulating tumor DNA (ctDNA) hold promise for guiding therapy. This evidence concerns the gene NF1 and neoplasm.